The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; X.sup.1 and X.sup.2 are independently, at each occurrence, CR.sup.5 or N; Y is C.sub.1-C.sub.6 alkylene, wherein alkylene is optionally substituted with one to two C.sub.1-C.sub.3 alkyl groups; R.sup.1 is selected from the group consisting of hydrogen, halogen, C.sub.1-C.sub.6 alkoxy, —NH.sub.2, —NHR.sup.6, —NR.sup.7R.sup.8 and —NH—(R.sup.9).sub.n—R.sup.10, n being 0 or 1; R.sup.2 is selected from the group consisting of hydrogen, halogen, C.sub.1-C.sub.6 alkyl, —NH.sub.2, —NHR.sup.6, —NR.sup.7R.sup.8 and —NH—(R.sup.9).sub.n—R.sup.10; R.sup.3 is selected from the group consisting of hydrogen, hydroxyl, OR.sup.11, —NR.sup.7R.sup.8, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.10 cycloalkyl, C.sub.1-C.sub.3 haloalkyl, —C(O)NHR.sup.11, aryl, heteroaryl and heterocyclyl, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R.sup.a groups; and R.sup.4 is selected from the group consisting of —NH.sub.2, —N(R.sup.12)(V).sub.pR.sup.13, —NH(V).sub.p—OR.sup.14, —NHC(O)R.sup.15, and groups of formula 1a shown below, and their use in the treatment of diseases, in particular inflammatory diseases, cancer, stroke and/or Alzheimer's disease. ##STR00001##

The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; X.sup.1 and X.sup.2 are independently, at each occurrence, CR.sup.5 or N; Y is C.sub.1-C.sub.6 alkylene, wherein alkylene is optionally substituted with one to two C.sub.1-C.sub.3 alkyl groups; R.sup.1 is selected from the group consisting of hydrogen, halogen, C.sub.1-C.sub.6 alkoxy, —NH.sub.2, —NHR.sup.6, —NR.sup.7R.sup.8 and —NH—(R.sup.9).sub.n—R.sup.10, n being 0 or 1; R.sup.2 is selected from the group consisting of hydrogen, halogen, C.sub.1-C.sub.6 alkyl, —NH.sub.2, —NHR.sup.6, —NR.sup.7R.sup.8 and —NH—(R.sup.9).sub.n—R.sup.10; R.sup.3 is selected from the group consisting of hydrogen, hydroxyl, OR.sup.11, —NR.sup.7R.sup.8, C.sub.1-C.sub.6 alkoxy, C.sub.1-C.sub.6 alkyl, C.sub.3-C.sub.10 cycloalkyl, C.sub.1-C.sub.3 haloalkyl, —C(O)NHR.sup.11, aryl, heteroaryl and heterocyclyl, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four R.sup.a groups; and R.sup.4 is selected from the group consisting of —NH.sub.2, —N(R.sup.12)(V).sub.pR.sup.13, —NH(V).sub.p—OR.sup.14, —NHC(O)R.sup.15, and groups of formula 1a shown below, and their use in the treatment of diseases, in particular inflammatory diseases, cancer, stroke and/or Alzheimer's disease. ##STR00001##

The invention relates to compounds of structural formula I

##STR00001##

wherein A, D, and E are independently N or C—R.sup.3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R.sup.3 or C—R.sup.3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R.sup.1 is selected from (C.sub.6 to C.sub.10) aryl, (C.sub.2 to C.sub.9) heteroaryl, and 5-indolyl, wherein each of the said (C.sub.6 to C.sub.10) aryl and (C.sub.2 to C.sub.9) heteroaryl is substituted with at least one R.sup.4a group, and wherein said (C.sub.2 to C.sub.9) heteroaryl is C-attached, and R.sup.2 is selected from the group consisting of

##STR00002##

The invention relates to compounds of structural formula I

##STR00001##

wherein A, D, and E are independently N or C—R.sup.3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R.sup.3 or C—R.sup.3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R.sup.1 is selected from (C.sub.6 to C.sub.10) aryl, (C.sub.2 to C.sub.9) heteroaryl, and 5-indolyl, wherein each of the said (C.sub.6 to C.sub.10) aryl and (C.sub.2 to C.sub.9) heteroaryl is substituted with at least one R.sup.4a group, and wherein said (C.sub.2 to C.sub.9) heteroaryl is C-attached, and R.sup.2 is selected from the group consisting of

##STR00002##

The present invention relates to potent antibacterial activity of novel bisbenzimidazoles (SP12a and SP12b) against both Gram positive and Gram negative bacteria and a synergistic composition comprising Bisbenzimidazole (HN12b) in combination with Efflux pump inhibitors against most of the pathogenic bacterial strains.

The present invention relates to potent antibacterial activity of novel bisbenzimidazoles (SP12a and SP12b) against both Gram positive and Gram negative bacteria and a synergistic composition comprising Bisbenzimidazole (HN12b) in combination with Efflux pump inhibitors against most of the pathogenic bacterial strains.

The present disclosure relates to an OLED that includes a first electrode; a second electrode facing the first electrode; a first emitting material layer including a first host being an anthracene derivative and a first dopant being a pyrene derivative and positioned between the first and second electrodes; and a first electron blocking layer including an electron blocking material of an amine derivative including a polycyclic aryl group and positioned between the first electrode and the first emitting material layer, wherein at least one of hydrogen atoms in the anthracene derivative and the pyrene derivative is deuterated.

The present disclosure relates to an OLED that includes a first electrode; a second electrode facing the first electrode; a first emitting material layer including a first host being an anthracene derivative and a first dopant being a pyrene derivative and positioned between the first and second electrodes; and a first electron blocking layer including an electron blocking material of an amine derivative including a polycyclic aryl group and positioned between the first electrode and the first emitting material layer, wherein at least one of hydrogen atoms in the anthracene derivative and the pyrene derivative is deuterated.

The present specification relates to an organic light emitting diode.

The present specification relates to an organic light emitting diode.